Expression of galectin-3 in the tumor immune response in colon cancer

Laboratory Investigation

Volumn 88, Issue 8, 2008, Pages 896-906

  Dumont, Patrick ^a   Berton, Alix ^a   Nagy, Nathalie ^a   Sandras, Flavienne ^a   Tinton, Sandrine ^a   Demetter, Pieter ^a   Mascart, Françoise ^a   Allaoui, Abdelmounaaïm ^b   Decaestecker, Christine ^b   Salmon, Isabelle ^a  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Colon cancer; Galectin 3; Immune response; M1 polarization; Macrophages

Indexed keywords

GALECTIN 3; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER IMMUNOLOGY; CANCER MODEL; CELL GROWTH; CELL POLARITY; CELLULAR IMMUNITY; COLON CANCER; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; DOWN REGULATION; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; MACROPHAGE ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; SUPERNATANT; TUMOR ASSOCIATED LEUKOCYTE;

ADENOCARCINOMA; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; CULTURE MEDIA, CONDITIONED; CYTOKINES; GALECTIN 3; HUMANS; INHIBITORY CONCENTRATION 50; LIPOPOLYSACCHARIDES; MACROPHAGES; RECEPTOR CROSS-TALK;

EID: 48749097847     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2008.54     Document Type: Article

References (37)

1. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-148.
2. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006;90:1-50.
3. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 2004;14:433-439.
4. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005;7:411-423.
5. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545.
6. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867.
7. Nakayama Y, Nagashima N, Minagawa N, et al. Relationships between tumor-associated macrophages and clinicopathological factors in patients with colorectal cancer. Anticancer Res 2002;22:4291-4296.
8. Tan SY, Fan Y, Luo HS, et al. Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer. World J Gastroenterol 2005;11:1210-1214.
9. Funada Y, Noguchi T, Kikuchi R, et al. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep 2003;10:309-313.
10. Forssell J, Oberg A, Henriksson ML, et al. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 2007;13:1472-1479.
11. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605-612.
12. Sica A, Schioppa T, Mantovani A, et al. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006;42:717-727.
13. Abe T, Ohno M, Sato T, et al. 'Differentiation induction' culture of human leukemic myeloid cells stimulates high production of macrophage differentiation inducing factor.. Cytotechnology 1991;5:S75-S93.
14. Simbirtsev A, Prokopieva E, Ivanova E, et al. Interleukin-1 and tumour necrosis factor production by human monocytoid cells: study on a single cell level. Eur Cytokine Netw 1992;3:421-428.
15. Auwerx J. The human leukemia cell line, THP-1: a multifacetted model for the study of monocyte-macrophage differentiation. Experientia 1991;47:22-31.
16. Legendre H, Decaestecker C, Nagy N, et al. Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers. Mod Pathol 2003;16:491-504.
17. Nagy N, Legendre H, Engels O, et al. Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting. Cancer 2003;97:1849-1858.
18. Hittelet A, Legendre H, Nagy N, et al. Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int J Cancer 2003;103:370-379.
19. Nakamura M, Inufusa H, Adachi T, et al. Involvement of galectin-3 expression in colorectal cancer progression and metastasis. Int J Oncol 1999;15:143-148.
20. Endo K, Kohnoe S, Tsujita E, et al. Galectin-3 expression is a potent prognostic marker in colorectal cancer. Anticancer Res 2005;25:3117-3121.
21. Dumic J, Dabelic S, Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006;1760:616-635.
22. Califice S, Castronovo V, Van Den Brüle F. Galectin-3 and cancer (review). Int J Oncol 2004;25:983-992.
23. Rabinovich GA, Baum LG, Tinari N, et al. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol 2002;23:313-320.
24. Sano H, Hsu DK, Yu L, et al. Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol 2000;165:2156-2164.
25. Perillo NL, Marcus ME, Baum LG. Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med 1998;76:402-412.
26. Nagy N, Brenner C, Markadieu N, et al. S100A2, a putative tumor suppressor gene, regulates in vitro squamous cell carcinoma migration. Lab Invest 2001;81:599-612.
27. Cecchinelli B, Lavra L, Rinaldo C, et al. Repression of the antiapoptotic molecule galectin-3 by homeodomain-interacting protein kinase 2-activated p53 is required for p53-induced apoptosis. Mol Cell Biol 2006;26:4746-4757.
28. Paik J, Duncan T, Lindahl T, et al. Sensitization of human carcinoma cells to alkylating agents by small interfering RNA suppression of 3-alkyladenine-DNA glycosylase. Cancer Res 2005;65:10472-10477.
29. Nakahara S, Oka N, Raz A. On the role of galectin-3 in cancer apoptosis. Apoptosis 2005;10:267-275.
30. Nangia-Makker P, Nakahara S, Hogan V, et al. Galectin-3 in apoptosis, a novel therapeutic target. J Bioenerg Biomembr 2007;39:79-84.
31. Schwende H, Fitzke E, Ambs P, et al. Differences in the state of differentiation of THP-1 cells induced by phorbol ester and 1,25- dihydroxyvitamin D3. J Leukoc Biol 1996;59:555-561.
32. Vaculova A, Hofmanova J, Soucek K, et al. Tumor necrosis factor-alpha induces apoptosis associated with poly(ADP-ribose) polymerase cleavage in HT-29 colon cancer cells. Anticancer Res 2002;22:1635-1639.
33. Castigli E, Arcuri C, Giovagnoli L, et al. Interleukin-1beta induces apoptosis in GL15 glioblastoma-derived human cell line. Am J Physiol Cell Physiol 2000;279:C2043-C2049.
34. Jensen-Jarolim E, Gscheidlinger R, Oberhuber G, et al. The constitutive expression of galectin-3 is downregulated in the intestinal epithelia of Crohn's disease patients, and tumour necrosis factor alpha decreases the level of galectin-3-specific mRNA in HCT-8 cells. Eur J Gastroenterol Hepatol 2002;14:145-152.
35. Karlsen AE, Størling ZM, Sparre T, et al. Immune-mediated beta-cell destruction in vitro and in vivo-A pivotal role for galectin-3. Biochem Biophys Res Commun 2006;344:406-415.
36. Sato S, Nieminen J. Seeing strangers or announcing 'danger': galectin-3 in two models of innate immunity. Glycoconj J 2004;19:583-591.
37. Nishi Y, Sano H, Kawashima T, et al. Role of galectin-3 in human pulmonary fibrosis. Allergol Int 2007;56:57-65.